BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2021 pay rises 1% to $18M
BioMarin Pharmaceutical reports 2021 executive compensation
By ExecPay News
Published: April 12, 2022
BioMarin Pharmaceutical reported fiscal year 2021 executive compensation information on April 12, 2022.
In 2021, five executives at BioMarin Pharmaceutical received on average a compensation package of $8.1M, a 14% increase compared to previous year.
Average pay of disclosed executives at BioMarin Pharmaceutical
Jean-Jacques Bienaim, Chief Executive Officer, received $18M in total, which increased by 1% compared to 2020. 62% of Bienaim's compensation, or $11M, was in stock awards. Bienaim also received $2.3M in non-equity incentive plan, $3.2M in option awards, $1.3M in salary, as well as $62K in other compensation.
For fiscal year 2021, the median employee pay was $175,523 at BioMarin Pharmaceutical. Therefore, the ratio of Jean-Jacques Bienaim's pay to the median employee pay was 104 to one.
Henry J. Fuchs, President, Worldwide R&D, received a compensation package of $6.9M, which decreased by 7% compared to previous year. 61% of the compensation package, or $4.2M, was in stock awards.
C. Greg Guyer, Chief Technical Officer and Executive Vice President of Global Manufacturing and Technical Operations, earned $5.4M in 2021, a 14% decrease compared to previous year.
Jeff Ajer, Executive Vice President, Chief Commercial Officer, received $5M in 2021, which increases by 10% compared to 2020.
Brian R. Mueller, Chief Financial Officer, earned $4.7M in 2021, a 20% decrease compared to previous year.
Related executives
Jean-Jacques Bienaim
BioMarin Pharmaceutical
Chief Executive Officer
Brian Mueller
BioMarin Pharmaceutical
Chief Financial Officer
Jeff Ajer
BioMarin Pharmaceutical
Executive Vice President, Chief Commercial Officer
Henry Fuchs
BioMarin Pharmaceutical
President, Worldwide R&D
C Guyer
BioMarin Pharmaceutical
Chief Technical Officer and Executive Vice President of Global Manufacturing and Technical Operations
You may also like
Source: SEC filing on April 12, 2022.